We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Phase 1 ALS Trial is First to Test Antisense Treatment of Neurodegenerative Disease

News   Apr 09, 2013

 
Phase 1 ALS Trial is First to Test Antisense Treatment of Neurodegenerative Disease
 
 
 

RELATED ARTICLES

Rubicon Alters Autophagy in Animals During Aging

News

Rubicon is a protein factor that suppresses autophagy by controlling a specific step in this pathway. This study found that Rubicon expression levels increased in an age-related manner in worm, fly, and mouse tissues.

READ MORE

Compound Could Help Treat Ovarian Cancer

News

Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

READ MORE

Gene Therapy Offers Hope for Reversing Congenital Deafness

News

Scientists have managed to restore hearing in an adult mouse model of DFNB9 deafness - a hearing disorder that represents one of the most frequent cases of congenital genetic deafness.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE